Fisher & Paykel Healthcare FY26 profit up 24% YOY

New Zealand-based medical device pioneer Fisher & Paykel Healthcare (ASX:FPH) has delivered its full-year financial result for 2026, lifting its total dividend by 22% on the back of a 24% rise in net profit.

The healthcare equipment manufacturer saw its net profit after tax climb to NZ$468.5 million for the 12 months ended March 31.

The milestone was achieved alongside a 14% increase in total operating revenue, which reached NZ$2.3 billion.

Driven by the numbers, the board approved a final dividend of 33 cents per share, pushing the full-year payout to 52 cents per share.

The company’s growth was supercharged by its core hospital products division, where consumables revenue rose 16% despite lower global hospital admission rates for seasonal respiratory conditions.

Managing Director and CEO Lewis Gradon noted that the result reflects a structural shift in medical treatments, indicating that changing clinical practice remains a powerful long-term growth catalyst for the company's therapies.

Management has issued confident guidance for the 2027 financial year, forecasting operating revenue to land between NZ$2.45 billion and NZ$2.57 billion, with net profit projected to rise further into a range of NZ$500 million to NZ$550 million.

At the time of reporting, Fisher & Paykel Healthcare’s share price was $29.73.